Atossa Genetics Inc news

   Watch this stock
Showing stories 1 - 10 of about 82   

Articles published

ATOS 1.52
price chart
Atossa Genetics (ATOS) Stock Declines Today on Heavy Trading Volume
"We rate ATOSSA GENETICS INC (ATOS) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the ...
Know before you invest: Atossa Genetics Inc (NASDAQ:ATOS), American ...  Markets Emerging
Related articles »  
Atossa Genetics Announces First Quarter 2015 Financial Results and Provides ...
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics.
Atossa Genetics Sponsors 8th Annual Walk with Love Fundraiser on May 17 ...  CNNMoney
Atossa Genetics (ATOS) Releases Quarterly Earnings Results, Misses Estimates ...  WKRB News
Atossa Genetics secures global license to Afimoxifene Gel (ATOS)
Atossa Genetics (ATOS +11.7%) inks a 15-year worldwide exclusive license agreement with Besins Healthcare Luxembourg SARL for its patented gel formulation of 4-Hydroxytamoxifen or Afimoxifene Gel for the potential treatment and prevention of ...
Atossa Genetics Acquires Rights to Clinical Stage Proprietary Afimoxifene ...  CNNMoney
Most Volatile Stocks: Atossa Genetics, Inc. (ATOS), Westlake Chemical ...  WallStreet Scope
Atossa Genetics: Spotty Track Record And Short On Cash (ATOS)
As a result the company improperly marketed its devices by using certain promotional claims to market the product not supported by the FDA.
Why gaining sharply? - Atossa Genetics Inc (ATOS), Penn Virginia Corporation ...  Markets Emerging
Atossa Genetics (ATOS) Gains; Henry Schein to Offer FullCYTE Breast Aspirator  StreetInsider.com
Atossa Genetics to Exhibit at Two Medical Conferences
Contact: Atossa Genetics, Inc.: Steven C. Quay, Ph.D., M.D. Chief Executive Officer and President (O) 800-351-3902 Kyle Guse CFO and General Counsel (O) 800-351-3902 Investor Relations: CorProminence LLC Scott Gordon President 516-222-2560 ...
Atossa Genetics Announces 2014 Financial Results and Provides Company ...
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics.
Atossa Genetics' (ATOS) CEO Steven Quay on Q4 2014 Results - Earnings ...  Seeking Alpha (registration)
Atossa Genetics Inc. (ATOS) Adopts Poison Pill Provision
Atossa Genetics Inc. (Nasdaq: ATOS) announced that its Board of Directors has approved the adoption of a stockholder rights agreement.
Why Atossa Genetics (ATOS) Stock Is Up Today  TheStreet.com
Related articles »  
Atossa Genetics Inc. Provides Update on Pharmacogenetics Testing Now ...
SEATTLE, WA, Dec 19, 2014 (Marketwired via COMTEX) -- Atossa Genetics Inc. ATOS, +0.00% today announced that its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), a CLIA-certified laboratory located in Seattle, ...
Related articles »  
Atossa Genetics Hires Cindy Atha as Vice President of Sales and Marketing
Atossa Genetics Inc. (NASDAQ: ATOS) today announced that Cindy Atha has joined the Company as Vice President of Sales and Marketing, effective May 4, 2015.
Seattle's Atossa Genetics completes pint-size IPO
After nearly nine months, Atossa Genetics of Seattle completed its initial public stock offering Thursday. But the final deal was even smaller than what the breast-cancer diagnostics company originally - and as recently as this week - had hoped ...
Atossa Genetics (ATOS) IPO Trades Lower  StreetInsider.com (subscription)